MassVentures

Invests in Massachusetts commercialization by helping ventures move from pilot activity into market-ready products.

MassVentures is Massachusetts' quasi-public venture capital corporation, founded in 1978 to accelerate the commercialization of deep tech and life sciences across the Commonwealth. It sits inside the state's economic-development system, combines a grant budget of about $4.5 million a year with an equity arm, and has built a long record around seed-stage companies that can turn federal research into a business.

Its grant programs are the clearest entry point for applicants. START is the flagship commercialization route for Massachusetts companies that have already won SBIR Phase II support, with a revised three-round structure that moves from $100,000 to $200,000 and then up to $500,000. Catalyst offers up to $75,000 for clean-energy projects led by Massachusetts-based research institutions or early-stage companies, while THRiVE provides up to $10,000 to institutions that sponsor international STEM entrepreneurs and commit to H-1B retention. Across these programs, the eligible sectors run through biotech, medtech, energy, manufacturing, AI infrastructure, robotics, quantum, aerospace, materials, and climate.

MassVentures is effective because it does not behave like a generic grantmaker. It pairs non-dilutive awards with venture investing, works directly on commercialization timing, and uses milestone-driven support to move teams from federal research into market traction. START opens only to companies that are Massachusetts-based, ready to commercialize, and already backed by SBIR Phase II money, while Catalyst and THRiVE each serve a narrower public purpose: clean-energy translation on one side and talent retention on the other. That mix gives MassVentures a sharper profile than a standard state fund and explains why it is often the state route for companies that need capital, not just encouragement.